Ophthalmology

It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake

October 25th 2022

By Skylar Jeremias

Speakers during a LinkedIn Live panel discussion expressed a dire need for all stakeholders to work together to increase education efforts, provide clarity on safety and interchangeability, and encourage adoption of biosimilars in ophthalmology.

Genentech, Roche Recall Ophthalmology Biobetter Susvimo

October 24th 2022

By Skylar Jeremias

Article

Genentech and Roche have voluntarily recalled their ophthalmology biobetter, Susvimo, an ocular implant for ranibizumab injection, in the United States for a possible leakage issue.

Eye on Pharma: 2 US Launches, an EMA Filing, and Denosumab Results

October 6th 2022

By Skylar Jeremias

Article

Recently, the US got 2 new biosimilars on the market, a bevacizumab and an interchangeable ranibizumab; Amneal Pharmaceuticals filed for marketing authorization in Europe; and Sandoz released positive results for a denosumab candidate.

Positive Results for Aflibercept Biosimilars Seen at AAO 2022

October 5th 2022

By Skylar Jeremias

Article

Two posters presented at the annual conference of the American Academy of Ophthalmology (AAO) demonstrated positive phase 3 results for proposed biosimilars that reference blockbuster drug, Eylea (aflibercept).

Coherus Rep Discusses Interchangeable Ophthalmology Biosimilar, Previews Onpro Competitor

September 28th 2022

By Skylar Jeremias

Video

Part 5 available now! Paul Reider, MBA, chief commercial officer at Coherus Biosciences, chronicles why Coherus got an interchangeable designation for its ophthalmology biosimilar, how it plans to set its adalimumab biosimilar apart from the rest, and when the pegfilgrastim market could see a competitor for Neulasta Onpro.

A Guide to Biosimilars for Retinal Diseases

September 24th 2022

By Deana Ferreri, PhD

Article

In a review article discussing the role of biosimilars in neovascular retinal diseases, the authors concluded that biologics have significantly improved patient outcomes, noting that vascular endothelial growth factor inhibitors are now considered first-line treatments.

Oncology, Ophthalmology Biosimilars Progress in Europe

September 19th 2022

By Skylar Jeremias

Article

As the United Kingdom adds another oncology biosimilar to its collection, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for another ranibizumab candidate.

European Commission Approves Second Lucentis Biosimilar

August 29th 2022

By Skylar Jeremias

Article

The European Commission granted marketing authorization to Teva’s ranibizumab biosimilar (Ranivisio), the second ophthalmology biosimilar and the second biosimilar to reference Lucentis to be approved in the European Union.

FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab

August 3rd 2022

By The Center for Biosimilars

Article

Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention of the prescribing clinician.

Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing

July 21st 2022

By Skylar Jeremias

Article

In recent weeks, Celltrion Healthcare furthered its adalimumab biosimilar (Yuflyma) by launching the drug in Spain and Portugal and starting a clinical trial in France while Xbrane Biopharma provided an update on the FDA filing of its ranibizumab biosimilar.